ethylmethylhydroxypyridine-succinate and Nervous-System-Diseases

We studied the effect of O-((((4-hydroxy-3,5-di(1,7,7-trimethylbicyclo[2.2.1]hept-exo-2-yl) benzyl)oxy)ethyl)-O-(2-hydroxyethyl)-(1→4)-α-D-glucan (D-HES, 80 mg/kg, intravenously) and reference preparation ethylmethylhydroxypyridine succinate (EMHP-S, 50 mg/kg, intravenously) on rat survival and neurological deficit in 24 h after transient global cerebral ischemia in Wistar rats. Intravenous administration of D-HES and EMHP-S significantly increased the number of survivors by 68 and 78%, respectively, in comparison with the control group. In groups treated with D-HES and EMHP-S, the number of animals with severe neurological deficit was significantly lower and the number of animals moderate or mild neurological deficit was significantly higher than in the control group.

Topics: Administration, Intravenous; Animals; Brain Ischemia; Drug Evaluation, Preclinical; Hydroxyethyl Starch Derivatives; Infusions, Intravenous; Ischemic Attack, Transient; Male; Nervous System Diseases; Neuroprotective Agents; Pyridines; Rats; Rats, Sprague-Dawley; Rats, Wistar